<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576223</url>
  </required_header>
  <id_info>
    <org_study_id>H-15008712</org_study_id>
    <secondary_id>2015-002391-24</secondary_id>
    <nct_id>NCT02576223</nct_id>
  </id_info>
  <brief_title>Suprascapular Nerve Block as Postoperative Analgesia After Artroscopic Shoulder Surgery</brief_title>
  <official_title>Suprascapular Nerve Block as Postoperative Analgesia After Artroscopic Shoulder Surgery - a Randomized, Blinded, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kai Henrik Wiborg Lange</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hillerod Hospital, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized study is to examine the effect of a selective suprascapular&#xD;
      nerve block on post operative pain after arthroscopic shoulder surgery. Half of the subjects&#xD;
      will receive a active nerve block with Ropivacain. Half of the subjects will receive a&#xD;
      placebo nerve block with saline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative pain management after arthroscopic shoulder surgery traditionally includes&#xD;
      opioids and/or an interscalene brachial plexus block(IBPB). Opioid consumption often leads to&#xD;
      unpleasant side effects including nausea, vomitting and sedation. IBPB offers very efficient&#xD;
      pain relief but includes the discomfort of a paralyzed arm. Furthermore this approach often&#xD;
      also leads to unilateral paresis of the phrenic nerve causing reduced respiratory capacity.&#xD;
      The latter offering discomfort and a potential risk in patients with lung diseases or heavy&#xD;
      overweight.&#xD;
&#xD;
      The suprascapular nerve is the most important nerve to the shoulder and a selective block of&#xD;
      this nerve could offer a good pain relief without the mentioned side effects.&#xD;
&#xD;
      In this randomized study the investigators wish to examine the pain relieving effect of a&#xD;
      selective block of the suprascapular nerve after arthroscopic shoulder surgery.&#xD;
&#xD;
      40 patients are randomized to a block of this nerve with either active drug (Ropivacaine) or&#xD;
      placebo (Saline). All patients will get a PCA (Patient Controlled Analgesia) pump for&#xD;
      administration of i.v. morphine in doses based on age and weight.&#xD;
&#xD;
      Patient are being monitored for 6 hours. The primary outcome is reduction in VAS at rest from&#xD;
      baseline to 30 minutes after nerve block.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) score at rest at T½</measure>
    <time_frame>30 minutes</time_frame>
    <description>Change in VAS score at rest from baseline to 30 minutes after nerve block (T½).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS score during maximum active shoulder abduction from T½ to T6</measure>
    <time_frame>6 hours</time_frame>
    <description>VAS scores measured at 7 timepoints (T½, T1, T2, T3, T4, T5, T6) during maximal active shoulder abduction and calculated as area under the curve (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS score at rest from T½ to T6</measure>
    <time_frame>6 hours</time_frame>
    <description>VAS scores measured at 7 timepoints (T½, T1, T2, T3, T4, T5, T6) at rest and calculated as area under the curve (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine consumption.</measure>
    <time_frame>6 hours</time_frame>
    <description>The total amount of morphine administered via the intravenous PCA pump the first 6 hours after nerve block.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electromyography at T½</measure>
    <time_frame>30 minutes</time_frame>
    <description>Change in activity of the infraspinatus muscle measured with surface electromyography from baseline to T½.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength at T½</measure>
    <time_frame>30 minutes</time_frame>
    <description>Change in strength of the supraspinatus (abduction of the shoulder) and the infraspinatus muscle (external rotation of the shoulder) measured with a handheld dynamometer from baseline to T½.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Ropivacaine hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ropivacain 7.5mg/ml, 5 ml injected perineural at the suprascapular nerve.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isotonic Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% Saline solution, 5 ml injected perineural at the suprascapular nerve.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine hydrochloride</intervention_name>
    <description>Ropivacaine injected perineural at the suprascapular nerve.</description>
    <arm_group_label>Ropivacaine hydrochloride</arm_group_label>
    <other_name>Ropivacaine, Naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic Saline</intervention_name>
    <description>Saline injected perineural at the suprascapular nerve.</description>
    <arm_group_label>Isotonic Saline</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients planned for arthroscopic shoulder surgery.&#xD;
&#xD;
          -  Age ≥ 18.&#xD;
&#xD;
          -  ASA class ≤ 3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with VAS never ≥5 mm during the first hour after arrivel to the post&#xD;
             anesthesia care unit.&#xD;
&#xD;
          -  Patients unable to cooperate.&#xD;
&#xD;
          -  Patients unable to understand or speak danish.&#xD;
&#xD;
          -  Allergy towards the used drugs.&#xD;
&#xD;
          -  Abuse of alcohol- and/or medicine - investigators assessment.&#xD;
&#xD;
          -  Usage of opioids on a daily basis (not including Tramadole).&#xD;
&#xD;
          -  Pregnancy (It is obligatory for all fertile women in the study to take a hcg urine&#xD;
             test).&#xD;
&#xD;
          -  Operations involving the clavicle.&#xD;
&#xD;
          -  Operations converted to open surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Steen-Hansen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nordsjællands Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Steen-Hansen</last_name>
    <email>christian.steen.hansen@regionh.dk</email>
  </overall_contact>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>October 14, 2015</last_update_submitted>
  <last_update_submitted_qc>October 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hillerod Hospital, Denmark</investigator_affiliation>
    <investigator_full_name>Kai Henrik Wiborg Lange</investigator_full_name>
    <investigator_title>Head of Research</investigator_title>
  </responsible_party>
  <keyword>Peripheral Nerve Blocks</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

